98
Participants
Start Date
December 6, 2017
Primary Completion Date
July 31, 2025
Study Completion Date
August 31, 2025
VBI-1901
The vaccine is formulated with GM-CSF adjuvant and administered intradermally (ID) or with AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.
Carmustine
Treatment with carmustine intravenously at a dose of 150 mg/m² on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.
Lomustine
Treatment with lomustine given orally at a dose of 110 mg/m² (up to a maximum dose of 200 mg) on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.
RECRUITING
The Neurological Institute of New York Columbia University Medical Center, New York
RECRUITING
Miami Cancer Institute, Miami
RECRUITING
Vanderbilt University Medical Center, Nashville
RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
University of California, Los Angeles Neuro-Oncology Program, Los Angeles
RECRUITING
University of California, San Diego, La Jolla
RECRUITING
University of California, Irvine, Irvine
RECRUITING
Stanford, Stanford
TERMINATED
Providence - Swedish Medical Center, Seattle
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Dana-Farber Cancer Institute, Boston
RECRUITING
The Valley Hospital - Neurosurgeons of New Jersey, Ridgewood
VBI Vaccines Inc.
INDUSTRY